News
Compounding Pharmacy Alerts and Recalls
Latest — updated August 10, 2026
Formulation and pharmacy watch:
Tirzepatide–B12 adduct finding keeps additive formulations under scrutiny
2026 laboratory work showing tirzepatide chemically bonds with added vitamin B12 — forming a molecule absent from any approved product — continues to anchor FDA concern about differentiated compounded formulations.
Monitored category — items publish only when newsworthy and sourced.
The pharmacy-alerts category tracks recalls, disciplinary actions, and safety communications involving compounding pharmacies that fulfill GLP-1 programs. Items name the pharmacy, product, lot where available, dates, the regulator, and any patient instructions.
What we watch in this category
- FDA recalls and safety alerts
- State board disciplinary actions
- Facility inspection findings
- Non-sterile or mislabeled compounded product warnings
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.